The historical rank and industry rank for Caribou Biosciences's Gross Margin % or its related term are showing as below:
CRBU's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.795 * Ranked among companies with meaningful Gross Margin % only.
Caribou Biosciences had a gross margin of N/A% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Caribou Biosciences was 0.00% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Caribou Biosciences had a gross margin of N/A% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Caribou Biosciences Gross Margin % Related Terms
Caribou Biosciences Gross Margin % Historical Data
* Premium members only.
The historical data trend for Caribou Biosciences's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CRBU vs YDES, PRQR, CRBP: Gross Margin % Comparison
For the Biotechnology subindustry, Caribou Biosciences's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Caribou Biosciences Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Caribou Biosciences's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Caribou Biosciences's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Caribou Biosciences (CRBU) has a Gross Margin % of 0.00% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Caribou Biosciences and its competitors. According to the industry distribution chart, Caribou Biosciences ranks #999999 out of 734 companies in the Biotechnology industry.
Is Caribou Biosciences' Gross Margin % too high?
Caribou Biosciences' current Gross Margin % is 0.00%. Based on the distribution chart, Caribou Biosciences ranks #999999 out of 734 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Caribou Biosciences has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Caribou Biosciences' Gross Margin % compare to YDES and PRQR?
According to the Biotechnology industry distribution chart, Caribou Biosciences ranks #999999 out of 734 companies for Gross Margin %. This places Caribou Biosciences in the lower half of its industry. The industry median Gross Margin % is 60.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.80, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Caribou Biosciences and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Caribou Biosciences's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caribou Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Caribou Biosciences (CRBU) is currently considered Fairly Valued. The stock's GF Value™ is $1.69, compared to a current price of $1.76 — trading 4.1% above its estimated fair value. The current Gross Margin % is 0.00%. Caribou Biosciences' overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Caribou Biosciences (CRBU), the current Gross Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Caribou Biosciences (CRBU) Overvalued in 2026?
Based on GuruFocus' analysis, Caribou Biosciences stock appears to be overvalued.
The current stock price of $1.76 is trading 4.1% above its estimated GF Value™ of $1.69.
GuruFocus considers Caribou Biosciences to be Fairly Valued.
Key valuation signals for CRBU:
Gross Margin %: 0.00%
GF Value™: $1.69 vs. price of $1.76 (4.1% above fair value)
No single metric tells the full story. See the CRBU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
65GF Score
Get the complete analysis for CRBU
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRBU has been successfully added to your 
